Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia

Date

14 Sep 2024

Session

Poster session 10

Topics

Genetic and Genomic Testing;  Genetic Testing and Counselling

Tumour Site

Breast Cancer

Presenters

Anni Lepland

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

M. Tamm1, P. Padrik2, A. Paas2, K. Kruuv-Käo2, S. Sõber2, L. Roht3, K. Ojamaa4, S. Pajusalu5, A. Padrik2, J. Pindmaa2, K. Luga6, L. Rootslane7, A. Ilves8, S. Ulp9, K. Kallak10, A. Tihamäe11, L. Leitsalu1, N. Tõnisson1

Author affiliations

  • 1 Institute Of Genomics, University of Tartu, 50090 - Tartu/EE
  • 2 Antegenes, OÜ Antegenes, 50603 - Tartu/EE
  • 3 Department Of Clinical Genetics, Tartu University Hospital, 50406 - Tartu/EE
  • 4 Haematology And Oncology Clinic, Tartu University Hospital, 50406 - Tartu/EE
  • 5 Genetics And Personalised Medicine Clinic, Department Of Personalised Medicine, Tartu University Hospital, 50406 - Tartu/EE
  • 6 General Medicine, OÜ Rapla Perearstikeskus, 79515 - Rapla/EE
  • 7 Pharmacy, AS Magnum, 76401 - Laagri/EE
  • 8 Women's Clinic, Tartu University Hospital, 50406 - Tartu/EE
  • 9 Radiology Clinic, Tartu University Hospital, 50406 - Tartu/EE
  • 10 Radio And Oncotherapy Department, Tartu University Hospital, 50406 - Tartu/EE
  • 11 Surgery Clinic, Tartu University Hospital, 50406 - Tartu/EE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1562P

Background

Breast cancer (BC) is the leading cause of cancer deaths in women. Current BC screening includes women over 50, but up to 20% of all BCs occur in younger women. Moreover, current mammography-based BC screening addresses up to 58% of all BC cases. Therefore, there is a need for new preventative screening strategies that are also cost-effective. In an international Be RIGHT with breast cancer risk management (BRIGHT) study, we used a polygenic risk score (PRS)-based screening to identify high-risk women in a population that does not attend routine mammography to show that PRS-based BC screening is cost-effective and has clinical utility.

Methods

In Estonia, 799 participants aged 35-49 were enrolled in the study between 2022-2023. For PRS testing, the AnteBC test (Antegenes OÜ) was used. The PRS was calculated based on 2803 BC-related genetic variants. Participants also self-filled a questionnaire about previous family cancer history for monogenic pathogenic variant (MPV) testing. All participants received a report with relevant clinical recommendations based on PRS levels. Both participants and investigators had the opportunity to fill in online feedback questionnaires.

Results

Based on PRS testing, 15.9% needed to start BC screening earlier and 58.8% according to national guidelines. From attended mammographies (154), 127 had no and 16 had benign findings. Five biopsies were taken and one stage 0 in situ intraductal BC was diagnosed. 80 participants received MPV testing, 5.7% had disease-related genetic findings. 98.3% of participants agreed that information provided was clear and sufficient, and 71.4% said they were coping well with knowing their genetic risks. 89% of investigators agreed that genetic risk in BC prevention is important based on the experience gained in BRIGHT study. 61% of investigators would definitely use the AnteBC test in clinical practice, time and need for extra knowledge were brought out as limiting factors.

Conclusions

The results of the BRIGHT study in Estonia indicate that PRS-based BC screening is feasible, has clinical utility and healthcare systems are ready for implementation. In Estonia, the addition of PRS into BC screening is planned within next few years.

Clinical trial identification

The BRIGHT study has been registered in the ISRCTN registry under ID ISRCTN29884654. Registration date 13.01.2023.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

European Commission via EIT Health (project #220720) and the Estonian Research Council PRG555 grant.

Disclosure

P. Padrik: Financial Interests, Institutional, Leadership Role: OÜ Antegenes. A. Paas, K. Kruuv-Käo, S. Sõber, A. Padrik, J. Pindmaa, Financial Interests, Institutional, Full or part-time Employment: OÜ Antegenes. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.